MBI
BCRX icon

May Barnhard Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

May Barnhard Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Hold
30,000
– – 0.12% 74
2026
Q1 		$286K Hold
30,000
– – 0.14% 72
2025
Q4 		$234K Hold
30,000
– – 0.11% 80
2025
Q3 		$228K Hold
30,000
– – 0.11% 80
2025
Q2 		$269K Hold
30,000
– – 0.13% 78
2025
Q1 		$225K Hold
30,000
– – 0.11% 85
2024
Q4 		$226K Hold
30,000
– – 0.11% 77
2024
Q3 		$228K Hold
30,000
– – 0.11% 77
2024
Q2 		$185K Buy
+30,000
New +$166K 0.1% 82

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

May Barnhard Investments's BCRX Position: Q2 2026 in Review

May Barnhard Investments held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 30,000 shares worth $300K. The position accounts for 0.12% of the portfolio, ranked #74.

May Barnhard Investments first reported a position in BCRX in Q2 2024 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • May Barnhard Investments held 30,000 shares of BioCryst Pharmaceuticals worth $300K as of Q2 2026.
  • May Barnhard Investments left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.12% of May Barnhard Investments's portfolio in Q2 2026, its #74 holding.
  • May Barnhard Investments first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on May Barnhard Investments's 13F filing for Q2 2026, filed 21 Jul 2026.